In 2019, the brand new bioLIVE China will be launched, as an upgrade from the seven-year-old biopharmaceutical platform BioPh China. bioLIVE China 2019 will focus on life science & technology and innovative drugs, aiming to  lead industrial trends and booster development in the biopharmaceutical area.

Leading the Pharmaceutical Trends in Asia

The biopharmaceutical industry is entering a blooming new age. The sales of biopharmaceutical drugs are expected to exceed 1/3 of the overall drug sales income. As per the statistics by InSight, the registrations of domestic bio drugs counted for 616 in year 2017, which exceeded the highest in the recent 5 years.
As is predicted by Frost & Sullivan, the market size of China’s bio drugs will reach 326.9 billion RMB, with its increase rate ranking among the highest countries in the world.

World-Class Annual Gathering of International Buyers

The bioLIVE zone is a gathering of high-end pharmaceutical ecosystem with half of attendees having decision making power

  • Manager/Project Manager/Head of Department 30.09%
  • CEO/President/Board Member/General Manager 19.60
    • R&D 16.67%
  • Technician/Engineer 11.79%
  • Product Manager 7.64%

Exhibitor Profiles

Biologics and New Therapies

  • Recombinant Protein
  • Polypeptide
  • Nucleic Acid
  • Vaccines
  • Plasma
  • Antibodies
  • Cell and Gene Therapy
  • Tumor Immunotherapy
  • Stem Cell & iPS

Bioprocessing, Manufacturing and Solutions

  • Cell Culture Media
  • Biological Reagents
  • Laboratory Consumables
  • Bioreactors
  • Bioseparation
  • Protein Purification
  • Bioprocessing
  • Software and Service

Biotechnology and R&D services

  • Molecular Biology
  • Cell Biology
  • Proteomics and Metabolomics
  • Biotechnology Service Platform
  • Detection Services
  • Biology Information Services
  • Drug R&D and Manufacturing
  • Clinical Research

CPhI China - Events & Zones

P-MEC China - Events & Zones